2021 China New Design Dmpa Photoinitiator - Hydroxypyrazolodpyrimidine pyrazolo(3,4-d)pyrimidin-1-ol – JIN DUN

It is clinically used in primary and secondary Hyperuricemia, especially in patients with hyperuricemia, as well as in patients with renal insufficiency, and in patients with recurrent or chronic gout, as well as in patients with Hyperuricemia. Used in patients with Gouty nephropathy to relieve symptoms and reduce the formation of renal uric acid stones; gout stones; used in uric acid kidney stones and uric acid kidney disease.

This product and its metabolites can inhibit xanthine oxidase, so that hypoxanthine and xanthine cannot be converted into uric acid, that is, the synthesis of uric acid is reduced, thereby reducing the concentration of uric acid in the blood and reducing the concentration of urate in the bones, Joints and kidneys, drugs that can inhibit the synthesis of uric acid. This product can inhibit the activity of liver drug enzymes.

(1) . Primary and secondary hyperuricemia, especially those with excessive uric acid production, are also used for hyperuricemia with renal insufficiency;

(2) . For the treatment of gout, suitable for recurrent or chronic gout. For patients with gouty nephropathy, it can relieve symptoms and reduce the formation of uric acid stones in the kidneys;

(3) . Tophi;

(4) . Used for uric acid kidney stones and (or) uric acid nephropathy.

Standard：usp42
Assay：98-102%

Exterior：White or almost white powder
Package : 25kg/bag

There is bone marrow suppression, which can cause pancytopenia, and the drug should be discontinued if necessary. Drink plenty of water during the medication, and make the urine neutral or alkaline to excrete diuretic acid. This product must be applied after the acute inflammation of gouty arthritis disappears (usually about two weeks after the onset). During medication, blood picture and liver and kidney function should be checked regularly.